The Utility of Advanced In Vitro Models in Toxicology and Disease Modeling

This FREE webinar was recorded on:
11:30 AM - 12:30 PM EST

Sponsored By:

The high rate of attrition among clinical-stage therapies underscores the need for in vitro models that recapitulate in vivo human biology. Using a proprietary 3D bioprinting platform, Organovo builds multi-cellular, three-dimensional (3D) human tissues with spatially-controlled architecture that enable biochemical, genetic, and histologic interrogation following exposure to modulators of interest, making them valuable in vitro tools for toxicology and disease modeling.  In this webinar, we will describe the basic characterization of 3D bioprinted human liver and kidney tissues and present case studies showing their utility in modeling human toxicity and organ-specific disease. This will tie in with our discussions on improving predictability, biomarker assessment and transporter studies.

Benefits of Attending

  • Understand the translational issue in drug discovery research today.
  • Gain an in-depth understanding of 3D bioprinting technology and its general application in biomedical research.
  • Become familiar with how 3D bioprinted human tissues from Organovo are being used to answer key questions in toxicology and disease modeling.

Challenges Tackled 

  • Costly failures of new drugs in clinical trials or early launch are due to an inability to properly predict human efficacy and safety with the existing preclinical model systems.
  • Creating better in vitro human model systems is challenging because of the need to include multiple cell types in a precise, defined 3D architecture to enable long term maintenance of native structure and function.
  • New advanced in vitro model systems must both accurately model human toxicity and disease pathology, as well as demonstrate reproducibility and scalability to enable practical routine use.

Solutions discussed 

  • Techniques such as 3D bioprinting can enable the automated, reproducible formation of complex in vitro tissues with precise, controlled 3D architecture.
  • Bioprinted tissues show enhanced functional longevity versus traditional culture systems.
  • Bioprinted liver and kidney tissues have been validated for their ability to detect multiple clinically relevant phenotypes of drug toxicity as well as modeling multi-factorial disease processes like fibrosis.

Who Should Attend?  

Professionals which fall into any of the following categories,

Pharmaceutical Scientists,  Toxicologists, Pathologists, Investigative Scientist, Disease Area Leads, Therapeutic Area Leads, Preclincal Development, Preclinical Safety, Safety Assessment, Translational Researcher at Pharmaceutical and Biotech companies

About the Predictive Toxicology Academy:  Following a series of successful real world conferences, to aid worldwide accessibility the Predictive Toxicology Academy brings you an evolving hub of online resources all accessible from the comfort of your desk. This November, the Academy will grow to become a library hosting a portfolio of various multimedia including live interactive sessions, whitepapers, podcasts, infographics, articles and interviews. Each week will have a fresh topic of focus within predictive toxicology.

Register for updates for the Predictive Toxicology Academy here today. 


Deborah Nguyen, PhD
Senior Director, R&D

Dr. Nguyen has spent more than a decade focusing on drug discovery and development.  During her tenure with the Genomics Institute of the Novartis Research Foundation (GNF), she gained significant experience in all phases of the drug discovery process from identifying new targets to drug candidate selection.  Dr. Nguyen then joined the rapidly growing Organovo team as Senior Director of R&D, with the goal of using the company’s proprietary bioprinting platform to create more predictive preclinical tissue models.  The technology has the potential to decrease the costs and increase the safety and efficacy of new drugs, as well as enabling clinical rescue of organ deficiency.  Dr. Nguyen received her PhD in Pharmacology from the Johns Hopkins School of Medicine.